PPP2R2D

Across TCGA pan-cancer cohorts, PPP2R2D Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PPP2R2D data layer compared with 20 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PPP2R2D Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PPP2R2D expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

ESCA, LUSC, and PRAD are the cancer types where PPP2R2D Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.117	0.703	<.001	36	view →
LUSC	DFS	Median	III,IV	0.079	0.658	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	OS	Median	All	0.238	0.697	.015	6	view →
STAD	DFS	Median	II,III,IV	1.000	0.327	.044	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PPP2R2D–ESCA (OS)

Open the ESCA breakdown →